TWiV 730: COVID-19 clinical update #53 with Dr. Daniel Griffin

<p>In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.</p> <p>Hosts: <a href="http://parasiteswithoutborders.com/">Daniel Griffin</a> and <a href= "http://en.wikipedia.org/wiki/Vincent_Racaniello">Vincent Racaniello</a></p> <p>Subscribe (free): <a href= "http://itunes.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?id=300973784">iTunes</a>, <a href="https://www.google.com/podcasts?feed=aHR0cDovL3R3aXYubWljcm9iZXdvcmxkLmxpYnN5bnByby5jb20vdHdpdg%3D%3D">Google Podcasts</a>, <a href= "http://twiv.microbeworld.libsynpro.com/twiv">RSS</a>, <a href="http://eepurl.com/Gcw59">email</a></p> <p>Become a <a href= "https://www.microbe.tv/contribute">patron</a> of TWiV!</p> <h3><strong>Links for this episode</strong></h3> <ul> <li><a href= "https://www.cdc.gov/mmwr/volumes/70/wr/mm7009a4.htm?s_cid=mm7009a4_x"> SARS-CoV-2 seroprevalence</a> in <18 year olds (MMWR)</li> <li>EUA for <a href= "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-adaptive-biotechnologies-t-detect-covid-test"> T cell test</a> (FDA)</li> <li>Lilly mAb <a href= "https://www.prnewswire.com/news-releases/lillys-bamlanivimab-and-etesevimab-together-reduced-hospitalizations-and-death-in-phase-3-trial-for-early-covid-19-301243984.html"> phase 3 results</a> (Lilly)</li> <li><a href= "https://www.globenewswire.com/news-release/2021/03/11/2190921/0/en/Vir-Biotechnology-and-GSK-Announce-VIR-7831-Reduces-Hospitalization-and-Risk-of-Death-in-Early-Treatment-of-Adults-with-COVID-19.html"> VIR-7831 mAb</a> phase 3 results (Globenewswire)</li> <li><a href= "https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/"> Molnupiravir</a> phase 2a results (Merc